- Revive Therapeutics has provided an update on its clinical study of oral psilocybin in the treatment of methamphetamine use disorder and the development of an oral psilocybin thin film strip
- The company is evaluating the use of oral psilocybin as a potential treatment for methamphetamine use disorder with the University of Wisconsin-Madison
- The phase I/II study evaluating the safety and feasibility of psilocybin in adults with methamphetamine use disorder received both FDA and Institutional Review Board approval
- Revive has initiated a program to develop and manufacture an oral psilocybin thin film strip for mental illness, substance abuse and neurological disorders
- Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders
- Revive Therapeutics Ltd. (RVV) opened trading at C$0.39
Revive Therapeutics (RVV) updates its clinical study of oral psilocybin to treat methamphetamine use disorder.
Derrick Welsh, COO of Psilocin Pharma, a division of Revive, commented on the update.
“We continue to focus on building a specialty psilocybin-based product pipeline to treat mental illness, substance abuse and neurological disorders. We intend to advance the development of our oral psilocybin thin film strip product for these indications. In parallel, we are working on our first clinical study evaluating oral psilocybin in the treatment of methamphetamine use disorder to validate its use in substance abuse indications. The clinical data from this study will be used to support late-stage clinical trials with our oral psilocybin thin film strip product.”
Under an investigator-initiated IND, the phase I/II clinical study to evaluate the safety and feasibility of psilocybin in adults with methamphetamine use disorder received both FDA and Institutional Review Board approval. The study is being conducted at the University of Wisconsin-Madison, School of Medicine and Public Health and School of Pharmacy.
The company has initiated the product development program with LTS Lohmann Therapie-Systeme AG, to develop and manufacture a proprietary oral psilocybin thin film strip product for mental illness, substance abuse and neurological disorders. Prototypes of the oral psilocybin thin film strip product have been developed and are being optimized for use in upcoming IND-enabling studies. Revive expects to conduct a first-in-human clinical study in 2023.
Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders.
Revive Therapeutics Ltd. (RVV) opened trading at C$0.39.